지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.87 No.1
- 발행연도
- 2014.6
- 수록면
- 9 - 13 (5page)
이용수
초록· 키워드
오류제보하기
Purpose: Chemotherapy-induced nausea and vomiting (CINV) have a negative impact on patients’ quality of life and frequently pointed to as a major factor for treatment abandonment. Serotonin (5-HT3) receptor antagonist is considered as key treatment for CINV. Ramosetron and palonosetron are recently developed 5-HT3 receptor antagonists and known as more superior than other first-generation 5-HT3 receptor antagonists. The purpose of this study was to compare the efficacy of ramosetron and palonosetron and determine which drug is more effective for prevention of CINV.
Methods: Colorectal cancer patients treated with chemotherapy were enrolled consecutively. Patients were assigned to receive intravenous injection of ramosetron 0.3 mg or palonosetron 0.25 mg at 30 minutes before initiation of moderately emetogenic chemotherapy. Ramosetron group added oral administration of 0.1 mg ramosetron on the second and third days of chemotherapy. Efficacy parameter consisted of nausea and vomiting.
Results: Ninety-one patients received ramosetron and 89 patients received palonosetron. Presentation of vomiting and nausea symptoms was not significantly different between the two groups during acute (0?24 hours) and delayed period (after 24 hours).
Conclusion: The incidence of CINV between the ramosetron and the palonosetron group has not shown any difference during acute, delayed, and overall period.
Methods: Colorectal cancer patients treated with chemotherapy were enrolled consecutively. Patients were assigned to receive intravenous injection of ramosetron 0.3 mg or palonosetron 0.25 mg at 30 minutes before initiation of moderately emetogenic chemotherapy. Ramosetron group added oral administration of 0.1 mg ramosetron on the second and third days of chemotherapy. Efficacy parameter consisted of nausea and vomiting.
Results: Ninety-one patients received ramosetron and 89 patients received palonosetron. Presentation of vomiting and nausea symptoms was not significantly different between the two groups during acute (0?24 hours) and delayed period (after 24 hours).
Conclusion: The incidence of CINV between the ramosetron and the palonosetron group has not shown any difference during acute, delayed, and overall period.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (20)
참고문헌 신청
1. [학술지(정기간행물)] - Griffin AM. / 1996 / On the receiving end. V : Patient perceptions of the side effects of cancer chemotherapy in 1993 / Ann Oncol 7 : 189 ~ 195
2. [학술지(정기간행물)] - Almeida EP. / 2004 / Monitoring and evaluation of side effects of chemotherapy in patients with colon cancer / Rev Lat Am Enfermagem 12 : 760 ~ 766
3. [학술지(정기간행물)] - Andrews PL. / 2002 / Abdominal vagal afferent neurones : an important target for the treatment of gastrointestinal dysfunction / Curr Opin Pharmacol 2 : 650 ~ 656
4. [학술지(정기간행물)] - Fukui H. / 1992 / Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs / Jpn J Pharmacol 59 : 221 ~ 226
5. [학술지(정기간행물)] - Hesketh PJ. / 2000 / Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting / Cancer Invest 18 : 163 ~ 173
2. [학술지(정기간행물)] - Almeida EP. / 2004 / Monitoring and evaluation of side effects of chemotherapy in patients with colon cancer / Rev Lat Am Enfermagem 12 : 760 ~ 766
3. [학술지(정기간행물)] - Andrews PL. / 2002 / Abdominal vagal afferent neurones : an important target for the treatment of gastrointestinal dysfunction / Curr Opin Pharmacol 2 : 650 ~ 656
4. [학술지(정기간행물)] - Fukui H. / 1992 / Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs / Jpn J Pharmacol 59 : 221 ~ 226
5. [학술지(정기간행물)] - Hesketh PJ. / 2000 / Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting / Cancer Invest 18 : 163 ~ 173
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2015-510-001669938